Impact of statin therapy on central aortic pressures and hemodynamics: Principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) study

Circulation

Volumn 119, Issue 1, 2009, Pages 53-61

  Williams, Bryan ^a   Lacy, Peter S ^a   Cruickshank, J Kennedy ^b   Collier, David ^c   Hughes, Alun D ^d   Stanton, Alice ^e   Thorn, Simon ^d   Thurston, Herbert ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e BEAUMONT HOSPITAL   (Ireland)

Author keywords

Blood pressure; Hypertension; Statins; Vasculature

Indexed keywords

ATENOLOL; ATORVASTATIN; PERINDOPRIL; PLACEBO;

ADULT; AORTA PRESSURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODYNAMICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TONOMETRY; TREATMENT OUTCOME;

AORTA; BLOOD PRESSURE; BRACHIAL ARTERY; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PLACEBOS; PULSATILE FLOW; PYRROLES; RADIAL ARTERY; TREATMENT OUTCOME;

EID: 59049105615     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.785915     Document Type: Article

References (27)

1. Williams B, Lacy PS, Thorn SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, for the CAFE and ASCOT Investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation study: the CAFE Study. Circulation. 2006;113:1213-1225.
2. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203.
3. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, Wang JG, Wilkinson IB, Williams B, Vlachopoulos C. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154-160.
4. Williams B, O'Rourke M, for the Anglo-Scandinavian Cardiac Outcomes Trial. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens. 2001;15(suppl 1):S69-S73.
5. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Mclnnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens. 2001;19:1139-1147.
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mclnnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
7. Cholesterol Treatment Trialists' (CTTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
8. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol. 2005;45:89-118.
9. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005;19:103-109.
10. Wilkinson IB, Cockcroft JR. Cholesterol, lipids and arterial stiffness. Adv Cardiol. 2007;44:261-277.
11. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007;49:792-798.
12. Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, Mclnnes G, Mehlsen J, Nieminem M, O'Brien E, Ostergren J, for the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27: 2982-2988.
13. Dart AM, Gatzka CD, Cameron JD, Kingwell BA, Liang Y-L, Berry KL, Reid CM, Jennings GL. Large artery stiffness is not related to plasma cholesterol in older subjects with hypertension. Arterioscler Thromb Vasc Biol. 2004;24:962-968.
14. Saba PS, Roman MJ, Longhini C, Scorzoni D, Pini R, Devereux RB, Ganau A. Carotid intimal-medial thickness and stiffness are not affected by hypercholesterolemia in uncomplicated essential hypertension. Arterioscler Thromb Vasc Biol. 1999; 19:2788-2794.
15. Smilde TJ, van den Berkmortel FW, Wollersheim H, van Langen H, Kastelein JJ, Stalenhoef AFH. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest. 2000;30:473-480.
16. Ubels FL, Muntinga JHJ, van Doormaal JJ, Reitsma WD, Smit AJ. Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. Atherosclerosis. 2001;154:155-161.
17. Wilkinson IB, Prasad K, Hall IR, Thomas A, MacCallum H, Webb DJ, Frenneaux MP, Cockcroft JR. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol. 2002;39:1005-1011.
18. van Trijp MJCA, Bos WJW, Uiterwaal CSPM, Oren A, Vos LE, Grobbee DE, Bots ML. Determinants of augmentation index in young men: the ARYA study. Eur J Clin Invest. 2004;34:825-830.
19. Ferrier KE, Muhlmann MH, Baguet J-P, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39:1020-1025.
20. Wassmann S, Luafs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, Nickenig G. HMG-Co A reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450-1457.
21. de Sotomayer AM, Perez-Guerrero C, Herrera MD, Marhuenda E. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens. 1999;17:769-776.
22. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid lowering medication. Lancet. 1995;346:467-471.
23. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation. 1997;95:1126-1131.
24. van Verooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD, for the DALI study group. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes. Diabetes Care. 2002;25:1211-1216.
25. Stein JH, Carlsson CM, Papcke-Benson K, Aeschlimann SE, Bodemer A, Carnes M, McBride PE. The effect of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia. J Am Coll Cardiol. 200l;38:1806-1813.
26. O'Rourke MF. Wave travel and reflection in the arterial system. J Hypertens. 1999;17(suppl 5):S45-S47.
27. Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Aortic input impedance in normal man: relationship to pressure waveforms. Circulation. 1980;62: 105-116.